Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
|Articles|October 9, 2019
PTI Inspection Systems
PTI is a global leader in package testing equipment. It specializes in non-destructive package testing equipment for high-risk packaging applications.
PTI is a global leader in package testing equipment. We specialize in non-destructive package testing equipment for high-risk packaging applications. PTI manufactures solutions for package integrity, leak detection, container closure integrity, and seal integrity testing. PTI’s technologies are deterministic test methods that produce reliable and robust quantitative test result data. We provide solutions for testing vials, ampoules, auto-injectors, cartridges, pre-filled syringes, and many other packaging formats.
Related to this article
Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.
BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.
Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.
Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
Phase 1 data presented at IDWeek 2026 show TaiMed Biologics’ host-directed antibody TMB-365 lowered HIV-1 RNA without resistance, as the company advances an antibody-only maintenance regimen with TMB-380.
Trending on BioPharm International
1
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5